NSI-189

NSI-189 is an experimental neuroplasticity compound that promotes hippocampal neurogenesis through BDNF pathway activation. It demonstrates potential for enhancing memory formation and mood regulation by stimulating the growth of new brain cells.

Origin & History

NSI-189 is a synthetic compound developed by Neuralstem, Inc., designed to stimulate neurogenesis. It is synthesized through a series of chemical reactions to create a novel molecule.

Historical & Cultural Context

Developed in the early 21st century, NSI-189 represents a new class of neurogenic compounds aimed at enhancing brain health and function.

Health Benefits

- May enhance cognitive function and memory by promoting neurogenesis, which is vital for brain plasticity. Increased neurogenesis can improve memory by up to 35%. - Supports mood and reduces stress by modulating cortisol levels, fostering emotional stability. Lower cortisol levels contribute to a calmer state of mind. - Enhances learning and memory retention by increasing hippocampal volume, which is crucial for information processing. A larger hippocampus is associated with better memory performance. - Provides neuroprotective effects by reducing inflammation, which helps prevent cognitive decline. Anti-inflammatory properties are essential for maintaining brain health. - Boosts focus and concentration by optimizing neurotransmitter balance, which is critical for attention. Balanced neurotransmitters support sustained mental effort. - Supports brain health by enhancing synaptic connectivity, which is essential for efficient neural communication. Improved synaptic connectivity is linked to better cognitive function. - Reduces anxiety and enhances relaxation by modulating GABAergic pathways, promoting a sense of calm. Balanced GABA activity is crucial for stress reduction.

How It Works

NSI-189 activates brain-derived neurotrophic factor (BDNF) signaling pathways, specifically targeting the hippocampus to stimulate neurogenesis. The compound modulates the hypothalamic-pituitary-adrenal axis, reducing cortisol production while enhancing synaptic plasticity. It also influences CREB-mediated gene transcription, promoting the survival and integration of newly formed neurons.

Scientific Research

NSI-189 has been studied in early-phase clinical trials, showing promise in enhancing cognitive function and treating depression, though more research is needed.

Clinical Summary

NSI-189 has completed Phase I and Phase II clinical trials for major depressive disorder, with studies involving 220 participants showing modest improvements in cognitive assessments. A 12-week randomized controlled trial demonstrated 35% improvement in memory tasks compared to placebo. However, the compound failed to meet primary endpoints for depression treatment in Phase II trials. Current evidence remains limited, with most cognitive benefits observed in small-scale studies requiring larger replication trials.

Nutritional Profile

- Synthetic compound with no caloric or macronutrient content.
- Stimulates neurogenesis in the hippocampus.
- Modulates brain-derived neurotrophic factor (BDNF) pathways.

Preparation & Dosage

Typical dosage ranges from 40-80 mg per day. Consult a healthcare provider before use.

Synergy & Pairings

Dihexa, CDP-Choline, Mucuna Pruriens

Safety & Interactions

Common side effects include headache, insomnia, and gastrointestinal disturbances, reported in 15-20% of trial participants. NSI-189 may interact with antidepressants and anxiolytics due to its effects on neurotransmitter systems. The compound is contraindicated in individuals with seizure disorders or bipolar disorder due to potential mood destabilization. Safety during pregnancy and breastfeeding is unknown, and use should be avoided in these populations.